基底细胞癌诊断与治疗:欧洲共识跨学科指南
该指南由欧洲皮肤病论坛、欧洲皮肤肿瘤协会和欧洲癌症研究与治疗组织专家共同制定,提出将基底细胞癌分为「易治」和「难治」两类,并给出诊断和治疗推荐。诊断基于临床皮肤镜特征,手术是易治基底细胞癌的一线治疗,Hedgehog抑制剂用于局部晚期和转移性基底细胞癌。
要点
- 提出「易治」与「难治」基底细胞癌新分类
- 易治基底细胞癌一线为完整手术切除
- 局部晚期和转移性基底细胞癌可用Hedgehog抑制剂
核心结论
- 提出基底细胞癌「易治」与「难治」新分类,并据此给出诊断和治疗推荐。
研究设计与样本
- 由欧洲皮肤病论坛、欧洲皮肤肿瘤协会和欧洲癌症研究与治疗组织专家协作制定的共识指南。
主要发现
- 易治基底细胞癌诊断基于临床皮肤镜特征,可疑病变和高危部位需组织病理学确认。
- 易治基底细胞癌一线治疗为完整手术,高危、复发和关键解剖部位基底细胞癌应提供显微镜控制手术。
- 低危浅表基底细胞癌可考虑局部治疗(5%咪喹莫特、5%氟尿嘧啶)和破坏性治疗(刮除、电灼、冷冻、激光消融)。
- 光动力疗法对浅表基底细胞癌和薄结节型基底细胞癌有效。
- 难治基底细胞癌治疗应优先由多学科肿瘤委员会讨论,局部晚期和转移性者可提供Hedgehog抑制剂维莫德吉或索尼德吉。
关键数值与推荐
- 易治基底细胞癌一线治疗为完整手术。
- 高危基底细胞癌、复发基底细胞癌和关键解剖部位基底细胞癌应提供显微镜控制手术。
- 低危浅表基底细胞癌可考虑5%咪喹莫特、5%氟尿嘧啶局部治疗或刮除、电灼、冷冻、激光消融等破坏性治疗。
- 光动力疗法适用于浅表基底细胞癌和薄结节型基底细胞癌。
- 局部晚期和转移性基底细胞癌应提供维莫德吉或索尼德吉。
临床怎么用
- 按「易治/难治」分类评估基底细胞癌,易治者首选完整手术。
- 高危、复发或关键部位基底细胞癌应行显微镜控制手术。
- 难治基底细胞癌应提交多学科肿瘤委员会讨论。
- 面部基底细胞癌尤其老年患者可考虑放疗作为手术替代。
- 痣样基底细胞癌综合征患者需密切监测和定期皮肤检查,高危亚型、高危部位、多发性基底细胞癌和NBCCS需长期随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Basal cell carcinoma (BCC) is the most common malignant tumour in white populations. Multidisciplinary experts from the European Dermatology Forum, the European Association of Dermato-Oncology and the European Organization of Research and Treatment of Cancer collaborated to develop recommendations on diagnosis and treatment of BCC. A new classification into 'easy-to-treat (common) BCC and 'difficult-to-treat' BCC is proposed. Diagnosis is based on clinicodermatoscopic features for 'easy-to-treat' BCCs. Histopathological confirmation is mandatory in ambiguous lesions and in BCCs located in high-risk areas. The first-line treatment of 'easy-to-treat' BCC is complete surgery. Microscopically controlled surgery shall be offered for high-risk BCC, recurrent BCC and BCC in critical anatomical sites. Topical therapies (5% imiquimod, 5% fluorouracil) and destructive approaches (curettage, electrocautery, cryotherapy, laser ablation) should be considered in patients with low-risk superficial BCC. Photodynamic therapy is an effective treatment for superficial BCC and thin nodular BCC. The therapy for a 'difficult-to-treat' BCC should preferentially be discussed by a multidisciplinary tumour board. Hedgehog inhibitors, vismodegib or sonidegib, should be offered to patients with locally advanced and metastatic BCCs. Immunotherapy with anti-programmed cell death 1 (PD-1) antibodies is a promising therapeutic option, currently being investigated in clinical trials. Radiotherapy represents a valid alternative to surgery for BCC on the face, especially in elderly patients. In patients with naevoid basal cell carcinoma syndrome (NBCCS), close surveillance and regular skin examinations are required to diagnose and treat BCCs at early stage. Long-term follow-up is recommended in patients with high-risk BCC subtypes, high-risk sites, multiple BCCs and NBCCS.
引用
- Peris K, Fargnoli MC, Garbe C, et al. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. Eur J Cancer. 2019. PMID: 31288208. doi:10.1016/j.ejca.2019.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。